Menotrophin Ferring-Léčiva

Menotrophin, the active ingredient in Menotrophin Ferring‑Léčiva, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It provides follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and ovulation in women with infertility.

GNH USA supplies Menotrophin Ferring‑Léčiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Menotrophin is used in reproductive medicine to support follicular growth and ovulation in women undergoing fertility treatment. - Infertility due to anovulation: stimulates follicular development and induces ovulation. - Controlled ovarian stimulation for assisted reproductive technology (ART): enables development of multiple mature follicles for IVF or ICSI cycles. - Ovarian stimulation in polycystic ovary syndrome (PCOS): helps achieve regular ovulation when other therapies are insufficient.

Menotrophin may cause a range of adverse reactions, most of which are related to its hormonal activity and injection route.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Nausea or mild gastrointestinal upset: transient and usually self‑limiting. - Headache: mild to moderate intensity. - Mild ovarian hyperstimulation: abdominal bloating or mild pelvic discomfort.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS): rapid weight gain, ascites, or respiratory distress. - Multiple pregnancy: higher-order gestations increase maternal‑fetal risk. - Allergic reaction or anaphylaxis: rash, urticaria, or breathing difficulty. - Thromboembolic events: rare clot formation associated with high estrogen levels.

Before initiating Menotrophin therapy, clinicians should assess patient history and monitor response closely. - Monitor ovarian response: perform serial ultrasound and estradiol measurements. - Assess OHSS risk: evaluate baseline ovarian reserve and prior stimulation history. - Adjust dose based on response: follow prescriber‑directed titration protocols. - Contraindicated in pregnancy: avoid use in confirmed pregnancy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other hormonal agents and medications that affect coagulation or vascular tone.

Major Interactions (Avoid): - GnRH agonists: may cause excessive ovarian stimulation. - hCG: can increase risk of severe OHSS when combined. - Dopamine agonists: may alter endogenous hormone levels and reduce efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may suppress baseline hormone levels, affecting response. - Anticoagulants: increase risk of bleeding at injection sites. - Thyroid hormones: may modify ovarian sensitivity to gonadotropins.